Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Vaccines

Free Subscription 02.06.2025 1 BMC Pediatr 1 BMJ 3 J Infect 1 Lancet 2 Pediatr Infect Dis J 4 PLoS One 30 Vaccine 1 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Pediatr

1. GOLLA EB, Geremew H, Abate A, Ali MA, et al
   Vaccination dropout and associated factors among children in Ethiopia: a systematic review and meta-analysis (2014-2024).
   BMC Pediatr. 2025;25:426.
   PubMed         Abstract available
   
   

   
   BMJ

2. TANNE JH
   US no longer recommends covid-19 vaccinations for pregnant women or children.
   BMJ. 2025;389:r1104.
   PubMed        
   
   

   
   J Infect

3. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
   Corrigendum to "Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: A cohort study" [J Infect 90 (2025) 106497].
   J Infect. 2025;91:106522.
   PubMed        
   
   
4. CHACON GP, McAlister S, Totterdell J, Estcourt MJ, et al
   Immune impacts of infant whole-cell and acellular pertussis vaccination on co-administered vaccines.
   J Infect. 2025 May 23:106515. doi: 10.1016/j.jinf.2025.106515.
   PubMed         Abstract available
   
   
5. BERTRAN M, Abdullahi F, D'Aeth JC, Amin-Chowdhury Z, et al
   Recurrent invasive pneumococcal disease in children: A retrospective cohort study, England, 2006/07-2017/18.
   J Infect. 2025;90:106490.
   PubMed         Abstract available
   
   

   
   Lancet

6. ATERE AO, Mustapha FB, Mustapha MJ
   Logistics of the malaria vaccine roll-out in Nigeria.
   Lancet. 2025;405:1815.
   PubMed        
   
   

   
   Pediatr Infect Dis J

7. GENTILE A, Juarez MDV, Lucion MF, Gregorio G, et al
   Maternal Immunization With RSVpreF Vaccine: Effectiveness in Preventing Respiratory Syncytial Virus-associated Hospitalizations in Infants Under 6 Months in Argentina: Multicenter Case-control Study.
   Pediatr Infect Dis J. 2025 May 28. doi: 10.1097/INF.0000000000004878.
   PubMed         Abstract available
   
   
8. PLOTKIN SA
   Bring Back Vaccinia!
   Pediatr Infect Dis J. 2025 May 21. doi: 10.1097/INF.0000000000004863.
   PubMed        
   
   

   
   PLoS One

9. NATALIA YA, Molenberghs G, Neyens T, Hens N, et al
   Empirical analysis of COVID-19 confirmed cases, hospitalizations, vaccination, and international travel across Belgian provinces in 2021.
   PLoS One. 2025;20:e0322017.
   PubMed         Abstract available
   
   
10. SONG MC, Ha J, Park S, Kang H, et al
    Mortality in severe serious adverse events following heterologous and homologous prime-boost vaccination strategies for SARS-CoV-2: A retrospective cohort study.
    PLoS One. 2025;20:e0323736.
    PubMed         Abstract available
    
    
11. BHAT KD, Bhattacharya H, Jayaraman Y, Kanungo S, et al
    Hepatitis B virus infection among children aged 1- 5 years of Mayurbhanj district (Odisha), India: A prospective study protocol.
    PLoS One. 2025;20:e0317621.
    PubMed         Abstract available
    
    
12. HAU SJ, Fittipaldi N, Payen S, Grenier D, et al
    Protection induced in pigs previously infected by the non-virulent strain 1330 of Streptococcus suis serotype 2 is not due to the secretion of the bacteriocin suicin.
    PLoS One. 2025;20:e0323370.
    PubMed         Abstract available
    
    

    
    Vaccine

13. YADAV G, Dandu H, Malhotra HS, Jain A, et al
    COVID-19 vaccination and utility of booster dose: A community-based cross-sectional study.
    Vaccine. 2025;60:127325.
    PubMed         Abstract available
    
    
14. HUNG CT, Wang LM, Liu DC
    National trends and disparities in herpes zoster vaccination coverage among U.S. older adults with cancer, 2008-2023.
    Vaccine. 2025;60:127326.
    PubMed         Abstract available
    
    
15. NASREEN S, Jiang Y, Lu H, Lee A, et al
    Risk of Guillain-Barre syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
    Vaccine. 2025;60:127291.
    PubMed         Abstract available
    
    
16. ESCOBAR-ZIEDE P, Borras-Bermejo B, Pinos-Tella L, Vivet-Escale M, et al
    Real-world effectiveness of MBA-VN vaccine against mpox, a test-negative case-control study.
    Vaccine. 2025;59:127295.
    PubMed         Abstract available
    
    
17. LIEN SB, Yang QW, Huang HW, Chiu KC, et al
    A novel immunogen comprising a bc loop and mutant fusion loop epitopes generates potent neutralization and protective abilities against flaviviruses without risk of disease enhancement.
    Vaccine. 2025;57:127219.
    PubMed         Abstract available
    
    
18. SIDORENKO SV, Rennert W, Zhdanov KV, Lobzin YV, et al
    Serotype dynamics of Streptococcus pneumoniae in some countries in Eastern Europe and Central Asia.
    Vaccine. 2025;57:127213.
    PubMed         Abstract available
    
    
19. STEPANEK L, Nakladalova M, Borikova A, Horakova D, et al
    Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort study.
    Vaccine. 2025;57:127232.
    PubMed         Abstract available
    
    
20. NG YF, Lockhart K, Dawar M, Vigor D, et al
    Assessing measles immunity among healthcare workers, a systematic review of peer-reviewed literature (2013-2023). Where do we go from here?
    Vaccine. 2025;57:127214.
    PubMed         Abstract available
    
    
21. ESPARZA J
    The illness of empress Maria Theresa as a trigger for the adoption of variolation in Austria (1768).
    Vaccine. 2025;58:127253.
    PubMed         Abstract available
    
    
22. HASAN Z, Masood KI, Qaiser S, Kanji A, et al
    Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains.
    Vaccine. 2025;59:127270.
    PubMed         Abstract available
    
    
23. SURI RK, Maugeais D, Maithal K
    COVID-19 pandemic: A multidimensional analysis and the strategic role played by developing countries vaccine manufacturers.
    Vaccine. 2025;59:127271.
    PubMed         Abstract available
    
    
24. GANDHI K, Vijay Y, Page K, Dahari H, et al
    Challenges in coverage of future hepatitis C vaccines: Review and potential solutions.
    Vaccine. 2025;59:127256.
    PubMed         Abstract available
    
    
25. KIBETI DM, Hoff NA, Merritt S, Lulebo AM, et al
    Quality and usability of home-based record photos to assess vaccine coverage: A case study from the 2022 Democratic Republic of the Congo Vaccine Coverage Survey.
    Vaccine. 2025;59:127248.
    PubMed         Abstract available
    
    
26. SHAHI N, Singh B, Pande A, Chandra S, et al
    Safe and efficacious inactivated immersion vaccine against KG+ phenotype of emerging bacterial pathogen Lactococcus garvieae for early developmental stage of rainbow trout (Oncorhynchus mykiss) in India.
    Vaccine. 2025;59:127266.
    PubMed         Abstract available
    
    
27. RAHIMI HK, Jasim AA, Rezahosseini O, Harboe ZB, et al
    Immunogenicity and adverse effects of pneumococcal vaccines co-administered with influenza or SARS-CoV-2 vaccines in adults: A systematic review and Meta-analysis.
    Vaccine. 2025;59:127293.
    PubMed         Abstract available
    
    
28. MOHAMED Y, Luey E, Kata ', Tukia O, et al
    "The only vaccine that we really question is the new vaccine": A qualitative exploration of the social and behavioural drivers of human papillomavirus (HPV) vaccination in Tonga.
    Vaccine. 2025;59:127280.
    PubMed         Abstract available
    
    
29. BAKHT P, Hussain A, Pandey S, Pathania R, et al
    Live attenuated hfq-deleted Acinetobacter baumannii vaccine provides protection against systemic infection.
    Vaccine. 2025;59:127298.
    PubMed         Abstract available
    
    
30. LAI SW, Liao KF
    Breakthrough herpes zoster risk after recombinant zoster vaccination.
    Vaccine. 2025 May 23:127294. doi: 10.1016/j.vaccine.2025.127294.
    PubMed        
    
    
31. LI M, Cai W, Chandrasekhar A, Hu H, et al
    Factors associated with primary care providers' recommendation of HPV vaccination for adolescent males in China: A mixed-methods study.
    Vaccine. 2025;59:127299.
    PubMed         Abstract available
    
    
32. ALSHURMAN BA, Majowicz SE, Grindrod K, Goh J, et al
    Understanding the shift in COVID-19 vaccine hesitancy and its associated factors for primary and booster doses among university students: A cross-sectional study.
    Vaccine. 2025;59:127296.
    PubMed         Abstract available
    
    
33. MALANGE V, Mohaissen T, Conway KM, Rhoads A, et al
    Influenza vaccination during early pregnancy and risk of major birth defects, US Birth Defects Study To Evaluate Pregnancy exposureS, 2014-2019.
    Vaccine. 2025;59:127297.
    PubMed         Abstract available
    
    
34. KROEGER M, Fano E, Sponheim A, Schwartz KJ, et al
    Assessment of homologous and heterologous PCV2 vaccine efficacy in a PCV2d/PRRSV co-challenge model.
    Vaccine. 2025;60:127303.
    PubMed         Abstract available
    
    
35. DEVKOTA B, Lal BK, Gautam A, Poudel L, et al
    Nationwide rollout of HPV vaccination in Nepal: Early key insights.
    Vaccine. 2025;60:127312.
    PubMed        
    
    
36. KATSEFF AS, Toumanios C, Barahim E, McCormick AA, et al
    PcrV in an intranasal adjuvanted tobacco mosaic virus conjugate vaccine mediates protection from Pseudomonas aeruginosa via an early Th1/Th17 skewed localized and systemic immune response.
    Vaccine. 2025;60:127306.
    PubMed         Abstract available
    
    
37. LEE N, Nguyen L, Nasreen S, Austin PC, et al
    Limited durability of protection conferred by XBB.1.5 vaccines against omicron-associated severe outcomes among community-dwelling adults, Ontario, Canada.
    Vaccine. 2025;60:127300.
    PubMed         Abstract available
    
    
38. SENPUKU K, Kunishima Y, Taniguchi K, Ito T, et al
    Development and characterization of MRC-5 and Vero cell-adapted enterovirus D68 strains for vaccine production.
    Vaccine. 2025;60:127314.
    PubMed         Abstract available
    
    
39. BHATIA D, Crowcroft N, Antoni S, Danovaro-Holliday MC, et al
    Prediction of subnational-level vaccination coverage estimates using routine surveillance data and survey data.
    Vaccine. 2025;60:127277.
    PubMed         Abstract available
    
    
40. SEILER P, Kaplan BS, Brice DC, Duan S, et al
    Altered germinal center responses in mice vaccinated with highly pathogenic avian influenza A(H5N1) virus.
    Vaccine. 2025;60:127311.
    PubMed         Abstract available
    
    
41. ABU-RAYA B, Giles ML, Kollmann T
    Co-administration of vaccines in pregnancy: unique challenges and knowledge gaps.
    Vaccine. 2025;60:127309.
    PubMed         Abstract available
    
    
42. ABE M, Shinmura Y, Tokieda Y, Mitsuhiro Y, et al
    A phase I, randomized, placebo-controlled, double-blind, ascending-dose and single-center study to evaluate immunogenicity and safety of a live attenuated tetravalent dengue vaccine (KD-382) in Flavivirus antibody-naive healthy adults.
    Vaccine. 2025;60:127313.
    PubMed         Abstract available
    
    

    
    Virology

43. CHOI KY, McGregor A
    The guinea pig as a relevant preclinical model in the rat race for a vaccine against congenital cytomegalovirus infection.
    Virology. 2025;610:110560.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.